Pyrrho Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

Pyrrho Capital Management’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-40,500	Closed	-$3.91M	–	37
2016 Q3	$3.91M	Buy	+40,500	New	+$3.85M	5.83%	4
2016 Q1	–	Sell	-90,000	Closed	-$10.2M	–	21
2015 Q4	$10.2M	Buy	+90,000	New	+$9.77M	6.85%	3

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Pyrrho Capital Management's IBB Position: Q4 2016 in Review

Pyrrho Capital Management sold out of iShares Biotechnology ETF (IBB) in Q4 2016, closing a stake of 40,500 shares — an estimated $3.91M sold.

Pyrrho Capital Management first reported a position in IBB in Q4 2015 and held it in 2 quarters. The position peaked at $10.2M in Q4 2015. 523 funds tracked by Wall St. Rank hold IBB as of Q4 2016.

Pyrrho Capital Management reported no remaining iShares Biotechnology ETF position as of Q4 2016 after selling out during the quarter.
Pyrrho Capital Management sold 40,500 iShares Biotechnology ETF shares in Q4 2016, an estimated $3.91M.
Pyrrho Capital Management first reported a position in iShares Biotechnology ETF in Q4 2015 and held it in 2 quarters.
Pyrrho Capital Management's iShares Biotechnology ETF position peaked at $10.2M in Q4 2015.
523 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q4 2016.

Based on Pyrrho Capital Management's 13F filing for Q4 2016, filed 10 Feb 2017.